NCT04258956 2025-09-11
AXAGIST
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Completed
Clinical Trials
13 trialsNCT04355156 2020-04-21
AXMUS-C
Imperial College London
Phase 2 Completed
NCT01334112 2019-12-12
AXITINIB
University Health Network, Toronto
Phase 2 Completed
NCT01490866 2019-09-24
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00219557 2019-05-14
AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Pfizer
Phase 2 Completed
NCT01210495 2019-01-09
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
Pfizer
Phase 2 Completed
NCT01352728 2018-06-20
Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib
Chinese University of Hong Kong
Phase 2 Completed
NCT01273662 2017-02-09
Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
National Taiwan University Hospital
Phase 2 Completed
NCT01486251 2016-02-10
AXUS
Gustave Roussy, Cancer Campus, Grand Paris
Phase NA Completed
NCT00460603 2013-12-06
Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
Pfizer
Phase 1/2 Completed
NCT00842244 2013-11-27
Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer
Pfizer
Phase 1 Completed
NCT00615056 2013-04-19
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Pfizer
Phase 2 Completed
NCT00471146 2012-07-16
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
Pfizer
Phase 3 Completed